Zoetis (ZTS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ZTS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

Eurizon Capital SGR S.p.A. lowered its position in shares of Zoetis Inc. (NYSE: ZTS) by 48.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund…

Commonwealth Equity Services LLC lowered its stake in Zoetis Inc. (NYSE: ZTS) by 24.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutiona…

ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jeff…

Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.…

Zoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrow…

Zoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from livestock healthcare sol…

Zoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call Participants Christoph…

Zoetis's organic operational revenue fell 1% in the third quarter. Global livestock revenue rose 7% to $797 million.…

Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.…

Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall…

Zoetis Inc. (NYSE:ZTS) reported third-quarter adjusted earnings of $1.75 per share, beating the consensus of $1.51.…

Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the …

Zoetis (ZTS) came out with quarterly earnings of $1.75 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.7 per share a year ago.…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Our third-quarter performa…

Zoetis is emerging from a period of underperformance, with market expectations for Q3 and Q4 set notably low. Consensus and management guidance anticipate revenue and EPS declines, but these expectations appear beatable …

ZTS heads into Q3 earnings with international growth, livestock strength and demand for key companion animal products offsetting U.S. market challenges.…

Evaluate the expected performance of Zoetis (ZTS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.…

In the most recent trading session, Zoetis (ZTS) closed at $78.8, indicating a +1.29% shift from the previous trading day.…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience ac…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, …

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartwor…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive…

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

